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Summary
Correct organ size is determined by the balance be-
tween cell death and proliferation. Perturbation of this
delicate balance leads to cancer formation [1]. Hippo
(Hpo), the Drosophila ortholog of MST1 and MST2
(Mammalian Sterile 20-like 1 and 2) is a key regulator
of a signaling pathway that controls both cell death
and proliferation [2, 3]. This pathway is so far com-
posed of two Band 4.1 proteins, Expanded (Ex) and
Merlin (Mer), two serine/threonine kinases, Hpo and
Warts (Wts), the scaffold proteins Salvador (Sav)
and Mats, and the transcriptional coactivator Yorkie
(Yki). It has been proposed that Ex and Mer act up-
stream of Hpo, which in turn phosphorylates and acti-
vates Wts. Wts phosphorylates Yki and thus inhibits
its activity and reduces expression of Yki target genes
such as the caspase inhibitor DIAP1 and the micro
RNA bantam [4–6]. However, the mechanisms leading
to Hpo activation are still poorly understood. In mam-
malian cells, members of the Ras association family
(RASSF) of tumor suppressors have been shown to
bind to MST1 and modulate its activity [7]. In this
study, we show that the Drosophila RASSF ortholog
(dRASSF) restricts Hpo activity by competing with
Sav for binding to Hpo. In addition, we observe that
dRASSF also possesses a tumor-suppressor function.
Results and Discussion
The mammalian RASSF family comprises six different
loci encoding a variety of splice variants. Most tran-
scripts encode proteins that contain a Ras association
domain (RA), an N-terminal C1-type zinc finger, and
a C-terminal SARAH (Sav RASSF Hippo) domain ([8–
13] and Figure S1A). RASSF family members, most nota-
blyRASSF1A, are frequently silenced in a variety of solid
tumors [14], mainly by promoter methylation [15]. Thus,
*Correspondence: nicolas.tapon@cancer.org.ukit has been proposed that RASSF genes act as tumor
suppressors.
The biological function of these genes is not well
understood. RASSF1A and Nore1A have both been
shown to interact with MST1 via its SARAH domain [7].
Overexpression of RASSF1A or Nore1A inhibits MST1
activation, but coexpression of these RASSF proteins
with Ras enhanced MST1 activity [16]. RASSF1A knock-
out mice have mildly increased tumor susceptibility [17],
confirming thatRASSF genes can act as tumor suppres-
sors. The weakness of the mouse phenotype, which is
at odds with the frequency of RASSF1A inactivation in
human tumors, can be ascribed to redundancy with
other family members.
By contrast, Drosophila melanogaster has a single
RASSF family member, which is encoded by the
CG4656 gene and which we will refer to as dRASSF.
Like its vertebrate counterparts,dRASSF encodes a pro-
tein bearing an RA and SARAH domain at its C terminus
(Figure S1A in the Supplemental Data available online). It
also possesses a LIM domain that shares some similar-
ities with C1 zinc fingers at its N terminus.
We generated mutant alleles of dRASSF by imprecise
excision of two nearby transposons, GE23517 and
EY2800 (see Supplemental Experimental Procedures).
We obtained multiple alleles, which delete up to the
fourth intron, including the initiating ATG (Figure S1B).
Some transcript was still detected in dRASSFX16,
dRASSFX36, but a strong reduction was found in
dRASSF44.2, which lacks the transcription start (Fig-
ure S1C). However, antibodies raised against the C
terminus (amino acids 792–806) and a nonconserved
region (amino acids 294–308) of dRASSF showed that
full-length dRASSF is absent in lysates from all mutant
lines, suggesting our dRASSF mutants are indeed loss-
of-function mutations for the locus (Figure S1D and
data not shown). All of these alleles were viable and
behaved identically in subsequent assays. In addition,
dRASSF staining was severely reduced in FLP/FRT-
generated dRASSF mutant clones in the eye-imaginal
disc, the larval precursor to the adult eye (Figure S1E).
Although thedRASSFmutant flies are viable, they pres-
ent a clear growth defect in comparison to wild-type
animals when reared in carefully controlled conditions
(Figure 1A). dRASSF mutant flies were 15% lighter than
their wild-type counterparts (Figure 1D), a phenotype
which was significantly rescued by introductionof a single
copy of a dRASSF rescue construct, although wild-type
levels of dRASSF were not fully restored (see Figure S1D).
dRASSF mutant flies were fully fertile and normally pro-
portioned (not shown) but sensitive to g-irradiation (Fig-
ure S1F). Wing surface area was reduced by 8% in
dRASSF mutant flies, whereas wing hair density was un-
affected (Figures 1B, 1C, 1E, and 1F). This suggests that
the growth defect of dRASSF mutant flies is due to a
reduction in cell number and not a defect in cell size.
In mammals, members of the RASSF family are
known to interact with MST1 and thus to modulate its
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2460Figure 1. dRASSF Controls Body Size
(A) white and dRASSFX16/X16 adult flies showing that dRASSF flies present a size defect.
(B–B00) dRASSFX16/X16 wings (B0) are smaller than white wings (B). (B00) Overlay of B and B0.
(C and C0) Cell density is not affected in dRASSFwings. Phase-contrast image of wing hairs on the wing surface ofwhite and dRASSFX16/X16 flies.
Note identical hair densities, indicating normal cell size in mutant wings.
(D) Histogram representing fly weights as percent of white control animals. dRASSF flies are 15% smaller than white flies. This weight defect is
partially rescued in the presence of the genomic rescue construct (GR). *p < 0.05 (white n = 120, dRASSFX16/X16 n = 120, dRASSFX16/X36 n = 90,
dRASSFX16/44.2 n = 90, GR;dRASSFX16/44.2 n = 90).
(E) Histogram representing wing areas as percent of control (white) wings. dRASSFX16/X16 wings are 8% smaller than control wings. *p < 0.05
(white n = 14, dRASSFX16/X16 n = 11).
(F) Histogram representing the number of trichomes in a defined wing area (see Supplemental Experimental Procedures) as a percent of control
(white). No significant difference was found between control and dRASSFX16/X16 wings (p > 0.05). white, n = 430; dRASSF, n = 432.
Error bars correspond to standard deviations.pro-apoptotic activity [7]. We therefore tested whether
dRASSF can interact with Hpo. We performed coimmu-
noprecipitation (Co-IP) experiments in Drosophila Kc
cells with dRASSF antibodies to immunoprecipitate
endogenous protein. As expected, dRASSF robustly
coimmunoprecipitated with Hpo (Figure 2A). The asso-
ciation between Hpo and Sav is mediated by these
proteins’ shared SARAH domains. Likewise, Hpo’s
SARAH domain is required for its association with
dRASSF, as shown by the fact that a truncated form of
Hpo (HpoDC) [18] lacking this domain fails to bring
down dRASSF (compare Figures 2B and 2C). Thus, the
Hpo SARAH domain can associate with both Sav and
dRASSF.Sav is stabilized by the presence of Hpo ([18, 19] and
Figure 2D, lane 2). We therefore tested whether dRASSF
levels are modulated by Hpo. dRASSF immunostaining
was reduced in clones mutant for a hpo allele that lacks
the SARAH domain (Figure 2F). In addition, RNAi-medi-
ated depletion of Hpo from Drosophila Kc cells resulted
in a reduction of endogenous dRASSF expression (Fig-
ure 2D), whereas dRASSF transcripts were unaffected
(Figure 2E). By contrast, dRASSF levels were unaffected
in clones mutant for other Hpo-pathway members, such
as ex (Figure 2G), sav, and wts (Figures S2A and S2B).
These results suggest that direct binding to Hpo through
its SARAH domain, rather than signaling through the
Hpo pathway, is necessary for dRASSF stability. This
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2461Figure 2. Hpo Interacts with dRASSF and
Controls Its Expression Levels
(A) Hpo coimmunoprecipitates with dRASSF.
Endogenous dRASSF was immunoprecipi-
tated from Kc cells lysates with dRASSF anti-
bodies or control (Myc antibodies). The Mem-
brane was blotted with Hpo66 and dRASSF
antibodies.
(B) Hpo coimmunoprecipitates with dRASSF
in Kc cells. Hpo-Flag and GFP-dRASSF
were cotransfected in Kc cells. dRASSF or
control (Myc antibodies) immunoprecipitates
were blotted for GFP-dRASSF and Hpo-Flag.
(C) Hpo lacking its SARAH domain (HpoDC)
does not interact with dRASSF. HpoDC-Flag
and GFP-dRASSF were cotransfected in
Kc cells. Anti-dRASSF or control (anti-Myc)
immunoprecipitates were blotted for GFP-
dRASSF and Hpo-Flag.
(D) Hpo controls dRASSF and Sav protein
levels. Kc cells were treated with GFP, Hippo,
Sav, or dRASSF dsRNAs. Lane 5 cells were
treated with GFP dsRNA and 3 hr of Stauro-
sporine (STS). Protein extracts were blotted
with dRASSF, Hpo66, Sav, P-MST1, and tu-
bulin antibodies. Hpo RNAi strongly reduces
both Sav and dRASSF protein levels.
dRASSF RNAi stabilizes Sav but is not suffi-
cient to induce Hpo phosphorylation.
(E) Hpo loss of function had no effect on
dRASSF mRNA expression. RT-PCRs per-
formed on Kc cell lysates treated with GFP
or Hpo RNAi. Hpo, dRASSF, and Actin
mRNA levels are shown.
(F–F00) Hpo controls dRASSF protein levels
in vivo. hpo mutant clones (marked by a lack
of GFP) were generated in eye discs via the
hpo42–48 allele. A robust reduction of dRASSF
staining (in red [F0]) is observed in hpo clones.
(G–G00) Ex does not affect dRASSF protein
levels. Clones of ex mutant cells (marked by
a lack of GFP) were generated in eye discs
via the exe1 allele. dRASSF (in red [G0]) stain-
ing is unaffected in the clones.is analogous to the situation for Sav, which is also stabi-
lized by a kinase-dead form of Hpo [18].
Because Hpo, Sav, and dRASSF all contain a SARAH
domain, we speculated that dRASSF might also bind
Sav. To test this, we investigated whether dRASSF inter-
acts with Sav by co-IP but repeatedly failed to detect
such an interaction (Figure S2C and data not shown).
Because the possibility of a ternary complex had been
raised by Scheel and Hofmann [13], we then tested
whether the three proteins could be found in the same
complex. We coexpressed Hpo, Sav, and dRASSF in
cultured Kc cells. As expected, Hpo was able to bind
Sav and dRASSF (Figure 3A). However, Sav immunopre-
cipitates only contained Hpo and not dRASSF, and
dRASSF immunoprecipitates contained Hpo but not
Sav (Figure 3A). We obtained identical results with en-
dogenous IPs by using dRASSF and Sav antibodies
(Figure S2C). These data support the notion that Savand dRASSF are not present in the same complex but
are in two different Hpo complexes.
Sav has been shown to be a positive regulator of
the Hpo pathway, whereas our genetic results suggest
that dRASSF might antagonize Hpo function. We were
therefore interested in determining whether complex-
ing with Sav or dRASSF might influence Hpo activity.
We probed our immunoprecipitates with an phospho-
MST1 antibody that recognizes phosphorylated (active)
Hpo [20]. Interestingly, although Hpo that was coimmu-
noprecipitated with dRASSF showed barely detectable
levels of phosphorylation, the Sav-associated fraction
was highly phosphorylated (Figure 3A). Thus, Hpo can
exist as two pools, a highly active Sav-associated pool
and an inactive dRASSF-associated pool. This corre-
lates with data showing that Nore1 can repress MST1
activity in mammalian cells [16]. This also suggests
that Sav can promote Hpo activation and provides
Current Biology
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interaction.
Next, we wanted to test our prediction that dRASSF
depletion would promote Hpo activation. Like that of
Hpo’s mammalian counterparts, phosphorylation of
endogenous Hpo can be potently stimulated by the
drug Staurosporine (STS) in Kc cells ([16, 20, 21] and
Figure 3B, lane 1). Although RNAi depletion of dRASSF
alone was not able to induce Hpo phosphorylation
(Figure 2D, compare lanes 4 and 5), dRASSF depletion
markedly potentiated STS-induced Hpo activation
(Figure 3B, compare lanes 1 and 2). Thus, dRASSF re-
stricts Hpo activation in cultured cells.
Given their opposing effects on Hpo activation, we in-
vestigated the relationship between Sav and dRASSF.
Depletion of dRASSF in Kc cells gives rise to an increase
in Sav protein levels (Figure 2D lines 1 and 4). Although
dRASSF levels were unaltered in sav mutant clones
(Figure S2A), overexpression of Sav in the wing disc
results in a robust decrease of dRASSF staining (Fig-
ure 3E). We then tested whether dRASSF and Sav com-
pete to bind Hpo. To address this question, because
Sav and dRASSF repress each other’s expression
and dRASSF has reduced affinity for phosphorylated
Hpo, we mixed separate Kc cell lysates expressing a
kinase-dead form of Hpo (HpoKD-Flag), Sav-HA, and
HA-dRASSF and performed IPs after the proteins were
allowed to bind overnight. Both Sav and dRASSF were
able to interact with Hpo (Figure 3C). In these conditions,
increasing the amount of Sav was able to displace the
dRASSF fraction bound to Hpo, showing that Sav and
dRASSF are competing to bind Hpo. The outcome of the
competition probably determines the stability of Sav
and dRASSF; both proteins are downregulated when
Hpo is depleted by RNAi (Figure 2D). Thus, we suggest
that interplay between the inhibitor dRASSF and the
activator Sav determines the level of Hpo activation
and therefore affects body size.
We tested this model by performing genetic-interac-
tion experiments. We crossed a mutant allele of hpo
into the dRASSF mutant background and measured
the adult body mass (Figure 3D). The body-mass reduc-
tion of dRASSF mutant flies (15% reduction) was sub-
stantially rescued by removal of just one copy of Hpo
(8% reduction). Flies overexpressing Sav showeda reduction of 10% in weight and 5% in wing area, mim-
icking dRASSF loss of function (Figure S3). This wing de-
fect was significantly increased in a dRASSF mutant
background (Figures S3B–S3D). In addition, misexpres-
sion of dRASSF was able to robustly rescue the rough-
eye phenotype elicited by coexpression of Sav and
Wts (Figures 3F–3I). These data support the notion that
dRASSF can antagonize Sav-mediated Hpo activation
in vivo.
Though our results are consistent with biochemical
data on mammalian RASSF family members [7, 16],
they are at odds with the fact that RASSF genes are
commonly silenced in tumor cells. Avruch and col-
leagues have proposed that one RASSF protein, Nore1,
possesses a tumor-suppressor function that is indepen-
dent of MST1 and MST2 [22]. We found two lines of evi-
dence to support this notion. First, we made clones that
are mutant for two hpo hypomorphic alleles, hpo42–48
([19] compare Figures 4C and 4F), hpoKC203 ([23] not
shown), that remove the SARAH domain in a dRASSF
mutant background in the head by using the eyeless
FLP system [24]. Interestingly, the overgrowth pheno-
type elicited by these hpo alleles was strongly enhanced
by loss of dRASSF. By contrast, a hpo allele (hpo42–47
[19]) bearing an inactivating deletion in the kinase
domain but an intact SARAH domain was barely if at
all enhanced by dRASSF loss of function (Figures 4B
and 4E). This suggests that dRASSF may possess a
tumor-suppressor function, which may be uncovered
when the Hpo function is compromised.
In addition, we examined the relationship between
Ras1 and dRASSF because the mammalian RASSF pro-
teins have all been shown to bind Ras proteins [8–10,
25]. In Drosophila imaginal tissues, Ras1 mutant clones
grow poorly and are eliminated by apoptosis ([26, 27]
and Figure 4G). When we made double-mutant clones
for Ras1 and dRASSF in the developing eye, we
observed a substantial rescue of the growth defect
observed in clones mutant for Ras1 alone (Figure 4H).
This rescue of Ras loss of function was the result of
both increased proliferation (Figure S4) quantified with
phosphorylated Histone 3 staining and a reduction of
apoptosis visualized with a cleaved-Caspase 3 antibody
(Figure S5). Thus, dRASSF appears to antagonize Ras1
signaling in growth control, which is again suggestive ofFigure 3. dRASSF Antagonizes Hpo Activity
(A) Hpo/Sav and Hpo/dRASSF are two distinct complexes. Hpo-Myc, Sav-HA, and GFP-dRASSF were cotransfected in Kc cells. Anti-Myc,
anti-HA, anti-dRASSF, or control (anti-Flag) immunoprecipitates were blotted for GFP-dRASSF, Sav-HA, Hpo-Myc, and phospho-MST1. Hpo
interacts with Sav and dRASSF (lane 2). Sav and dRASSF interact only with Hpo and not with each other (lanes 3 and 4). The Hpo fraction bound
to Sav is highly phosphorylated (lane 3), and that bound to dRASSF is not (lane 4).
(B) dRASSF inhibits Hpo phosphorylation. Kc cells were treated for 4 days with eGFP, dRASSF, or Hpo dsRNAi. The addition of STS 3 hr prior to
lysis induced Hpo phosphorylation (lane 1). Western blots were probed with dRASSF, Hpo34, and phospho-MST1 antibodies. In the presence of
dRASSF dsRNAi, Hpo phosphorylation increased (lane 2). As expected, the Hpo band disappeared upon Hpo dsRNAi treatment (lane 3).
(C) Sav competes with dRASSF to bind Hpo. Kc cell lysates expressing, respectively, HpoKD-Flag, HA-dRASSF, Sav-HA (200 ng), and Sav-HA
(400 ng) were mixed, incubated overnight, and immunoprecipitated with Flag antibody. Blots were probed with HA and Flag antibodies. Increas-
ing the amount of Sav displaced dRASSF from HpoKD (compare lanes 5 and 6).
(D) The dRASSF phenotype is sensitive to hpo loss of function. The histogram represents the total body weight as a percent of control flies
(white). The reduction in body size in dRASSF flies can be partially rescued by removal of one copy of hpo (hpo42–48 allele). *p < 0.05 (white
n = 80, dRASSFX16/X16 n = 80, FRT42D, hpo42–48/+ n = 80, and FRT42D, hpo42–48/+; dRASSFX16/X36 n = 80).
(E–E00 0) Sav controls dRASSF protein level. GFP (in green) and Sav were expressed in the posterior half of the wing disc by the engrailed-GAL4
(en-GAL4) driver. A robust reduction ofdRASSFstaining (in red [E0])wasobserved in theendomain. [E00 0] shows Sav overexpression in a separatedisc.
(F–I) dRASSF reduces apoptosis induced by sav and wts coexpression. Shown are scanning electron micrographs of Drosophila heads
from GMR::Gal4 control animals (F) or from GMR::Gal4/UAS::dRASSF (G), GMR::Gal4;GMR::sav+wts (H), or (I) GMR::Gal4/UAS::dRASSF;GMR::
sav+wts (I). Overexpression of dRASSF inhibits the rough-eye phenotype generated by coexpression of Sav and Wts.
See Supplemental Experimental Procedures for exact genotypes. Error bars correspond to standard deviations.
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dRASSF
(A–C, E, and F) Scanning Electron Micro-
graphs of Drosophila heads from control
animals (A), animals bearing hpo42–47 clones
(B), hpo42–48 clones (C), hpo42–47 clones in
a dRASSF loss-of-function background (E),
or hpo42–48 clones in a dRASSF loss-of-func-
tion background (F). The overgrowth pheno-
type elicited by the loss of hpo is enhanced
by the removal of dRASSF. See Supplemen-
tal Experimental Procedures for genotypes.
(D) Schematic representation of Hpo protein
showing the different mutations used. The
hpo42–47 allele causes a deletion of six amino
acids in the kinase domain, and this deletion
probably inhibits Hpo-ATP binding. The
hpo42–48 allele is a deletion of 20 bp and gives
rise to a premature stop codon. hpoKC203
changes G to A at the 50 splicing site and
the translation run into a stop codon in the
intron.
(G–H00) dRASSF rescues Ras1 loss of func-
tion. (G–G00) Ras1c40b clones (marked by a
lack of GFP) are small. (H–H00) Rasc40b
dRASSFX36 clones (marked by a lack of GFP)
are larger thanRasc40b clones. dRASSF stain-
ing is in red (G0 and H0).a ‘‘tumour-suppressing’’ effect distinct from its ‘‘onco-
genic’’ role in opposing the Hpo pathway. However,
Aoyama et al. suggest that NORE1 may also have both
Ras- and MST-independent functions [22]. Future
experiments will therefore be aimed at gaining a better
understanding of the RASSFs’ growth-restricting func-
tions. The fact that the dRASSF mutations are viable
might therefore reflect the facts that its ability to regulate
the Hpo pathway may be redundant with other modes of
regulation and that loss of dRASSF’s tumor-suppressive
activity is balanced by loss of its growth-promoting
activity. O’Neill et al. have proposed that MST2 may be
inactivated by binding to Raf-1. It will be interesting to
determine whether this mode of regulation is redundant
with RASSF [28].
In summary, we have generated mutant alleles of the
sole Drosophila ortholog of the RASSF family of tumor
suppressors. Surprisingly, dRASSF mutant flies are
smaller than control flies. This growth defect can proba-
bly be ascribed in part to dRASSF’s ability to antagonize
Hpo signaling by competing with Sav for binding to Hpo.
In addition, we have shown that dRASSF also possesses
a tumor-suppressor activity, which is uncovered when
hpo or Ras1 function is compromised. It will be interest-
ing to investigate whether some mammalian RASSF
proteins share these properties.Supplemental Data
Supplemental Data include Experimental Procedures and Five Fig-
ures and are available online at http://www.current-biology.com/
full/16/24/2459/DC1/.
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